Epigenomics Valuation
| EPGNF Stock | USD 0.79 0.00 0.00% |
Epigenomics is overvalued. Epigenomics AG shows a prevailing Real Value of $0.66 per share. The current price of the firm is $0.79. Our model computes the value of Epigenomics AG from reviewing the firm fundamentals such as Shares Outstanding of 4.09 M, operating margin of (15.90) %, and Shares Owned By Insiders of 35.00 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Epigenomics' price fluctuation is very steady at this time. Calculation of the real value of Epigenomics AG is based on 3 months time horizon. Increasing Epigenomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Epigenomics pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Epigenomics AG. Since Epigenomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Epigenomics Pink Sheet. However, Epigenomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.79 | Real 0.66 | Hype 0.79 | Naive 0.79 |
The real value of Epigenomics Pink Sheet, also known as its intrinsic value, is the underlying worth of Epigenomics AG Company, which is reflected in its stock price. It is based on Epigenomics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Epigenomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Epigenomics AG helps investors to forecast how Epigenomics pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Epigenomics more accurately as focusing exclusively on Epigenomics' fundamentals will not take into account other important factors: Epigenomics Total Value Analysis
Epigenomics AG is currently estimated to have takeover price of (9.71 M) with market capitalization of 6.01 M, debt of 966 K, and cash on hands of 15.77 M. The negative valuation of Epigenomics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the Epigenomics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(9.71 M) | 6.01 M | 966 K | 15.77 M |
Epigenomics Investor Information
About 35.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.39. Some equities with similar Price to Book (P/B) outperform the market in the long run. Epigenomics AG recorded a loss per share of 0.3. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 27th of December 2022. Based on the key indicators related to Epigenomics' liquidity, profitability, solvency, and operating efficiency, Epigenomics AG is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Epigenomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Epigenomics has an asset utilization ratio of 25.15 percent. This implies that the Company is making $0.25 for each dollar of assets. An increasing asset utilization means that Epigenomics AG is more efficient with each dollar of assets it utilizes for everyday operations.Epigenomics Ownership Allocation
Epigenomics AG retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Epigenomics Profitability Analysis
The company reported the revenue of 6.2 M. Net Loss for the year was (2.43 M) with profit before overhead, payroll, taxes, and interest of 6.07 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Epigenomics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Epigenomics and how it compares across the competition.
About Epigenomics Valuation
The pink sheet valuation mechanism determines Epigenomics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Epigenomics. We calculate exposure to Epigenomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Epigenomics's related companies.Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 36 people.
8 Steps to conduct Epigenomics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Epigenomics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Epigenomics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Epigenomics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Epigenomics' revenue streams: Identify Epigenomics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Epigenomics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Epigenomics' growth potential: Evaluate Epigenomics' management, business model, and growth potential.
- Determine Epigenomics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Epigenomics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Epigenomics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Epigenomics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 15.5 M | |
| Retained Earnings | -93.2 M |
Complementary Tools for Epigenomics Pink Sheet analysis
When running Epigenomics' price analysis, check to measure Epigenomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Epigenomics is operating at the current time. Most of Epigenomics' value examination focuses on studying past and present price action to predict the probability of Epigenomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Epigenomics' price. Additionally, you may evaluate how the addition of Epigenomics to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |